<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613520</url>
  </required_header>
  <id_info>
    <org_study_id>BSPZV2</org_study_id>
    <nct_id>NCT02613520</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants</brief_title>
  <official_title>Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium Falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanaria Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ifakara Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Care Development, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tanzania Commission for Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Government of Equatorial Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marathon Oil Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Noble Oil Services</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanaria Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial will evaluate safety and tolerability as well as the vaccine-induced&#xD;
      humoral and cellular immune responses in healthy Tanzanian adults, adolescents, children, and&#xD;
      infants who receive doses of 1.8x10^6, 9.0x10^5, 4.5x10^5 or 2.7x10^5 PfSPZ of PfSPZ Vaccine&#xD;
      by direct venous inoculation (DVI),compared with control groups receiving normal saline (NS)&#xD;
      placebo by DVI. In addition, as an exploratory objective, controlled human malaria infection&#xD;
      (CHMI) will be used to assess efficacy in adults three weeks following immunization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center trial to assess the safety, tolerability and immunogenicity of PfSPZ&#xD;
      Vaccine administered by direct venous inoculation (DVI) to healthy Tanzanian adults,&#xD;
      adolescents, and children and infants. 105 healthy male and female; adults, adolescents,&#xD;
      children and infant volunteers, aged from 6 months to 45 years, who live in the Bagamoyo&#xD;
      Township will be enrolled based on pre-defined inclusion and exclusion criteria implemented&#xD;
      according to international ethical standards.&#xD;
&#xD;
      The safety and tolerability of PfSPZ Vaccine administered as three doses of either 9.0x10^5&#xD;
      PfSPZ or 1.8x10^6 PfSPZ to healthy Tanzanian adults, adolescents, and children 6 years of age&#xD;
      or older; and three doses of 4.5x10^5 PfSPZ or 9.0x10^5 PfSPZ to healthy Tanzanian children 1&#xD;
      to 5 years of age and infants 6 to 11 months of age, in each case compared to NS controls,&#xD;
      will be evaluated. In addition, as an exploratory objective, controlled human malaria&#xD;
      infection (CHMI) will be used to assess efficacy in adults three weeks following&#xD;
      immunization.&#xD;
&#xD;
      Study Design: This is a single center trial with ten groups (Groups 1a/b: ages 18-45; Group&#xD;
      2a/b: ages 11-17; Group 3a/b: ages 6-10; Group 4a/b: ages 1-5; and Group 5b/c: ages&#xD;
      6months-11 months) each with 6 subjects receiving PfSPZ Vaccine and 3 subjects receiving NS&#xD;
      and an eleventh smaller group (Group 5a: ages 6months-11months) with 3 subjects receiving&#xD;
      PfSPZ Vaccine; two of these groups (Group 1a/b) contain adult volunteers and will have&#xD;
      infectivity controls (CHMI 1 and 2) each having 3 subjects, after the vaccination phase of&#xD;
      the study. The adult volunteers will undergo CHMI 3 weeks after the last immunization.&#xD;
&#xD;
      For the first immunization, two volunteers (out of six) in Group 1a will receive 9x10^5 of&#xD;
      PfSPZ Vaccine by DVI as sentinels, to demonstrate safety and tolerability. At the same time,&#xD;
      one (out of three) corresponding control volunteers will receive NS, in order to maintain&#xD;
      blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting&#xD;
      are not met, the remaining four volunteers in Group 1a will also receive a 9x10^5 PfSPZ dose&#xD;
      of the vaccine and the remaining two placebo recipients will receive NS.&#xD;
&#xD;
      After review of at least +14 days post vaccination safety data for Group 1a by the SMC, if&#xD;
      there are no significant safety concerns, two volunteers (out of six) in Group 1b will&#xD;
      receive 1.8x10^6 PfSPZ, and two volunteers (out of six) in each of the Groups 2a and 3a will&#xD;
      receive 9x10^5 PfSPZ, of the PfSPZ Vaccine, to demonstrate safety and tolerability, and each&#xD;
      of these sentinel groups will be joined by one corresponding NS control in order to maintain&#xD;
      blinding. Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting&#xD;
      are not met, the remaining four volunteers in Group 1b will receive 1.8x10^6 PfSPZ and the&#xD;
      remaining four volunteers in each of Groups 2a and 3a will receive 9x10^5 PfSPZ of the PfSPZ&#xD;
      Vaccine, and the remaining placebo recipients will receive NS.&#xD;
&#xD;
      After review of at least +14 days post vaccination safety data for Groups 1b, 2a and 3a by&#xD;
      the SMC, if there are no significant safety concerns, two volunteers (out of six) in each of&#xD;
      the Groups 2b and 3b will receive 1.8x10^6 PfSPZ, those in Group 4a will receive 4.5x10^5&#xD;
      PfSPZ and all 3 volunteers in Group 5a will receive 2.7x10^5 PfSPZ of PfSPZ Vaccine, to&#xD;
      demonstrate safety and tolerability, and each of the sentinel groups (two volunteers from&#xD;
      Groups 2b, 3b and 4a) will be joined by one NS control in order to maintain blinding.&#xD;
      Approximately 24 hours later, provided criteria for calling an ad hoc SMC meeting are not&#xD;
      met, the remaining four volunteers in Groups 2b, 3b and 4a will receive their appropriate&#xD;
      dose of PfSPZ Vaccine (1.8x10^6 PfSPZ, 1.8x10^6 PfSPZ, and 4.5x10^5 PfSPZ, respectively), and&#xD;
      the placebo recipients will receive NS.&#xD;
&#xD;
      Escalation from the small group of infants, (Group 5a, n=3) receiving a single dose of&#xD;
      2.7x10^5 PfSPZ, to the full group (Group 5b, n=6) receiving three doses of 4.5x10^5 PfSPZ,&#xD;
      will proceed without SMC review if criteria for calling an ad hoc SMC meeting are not met.&#xD;
      However, if the criteria are met, an ad hoc SMC meeting will be called to review the data,&#xD;
      and dose escalation to 4.5x10^5 PfSPZ will be postponed until the recommendations of the SMC&#xD;
      are available. The interval between the 2.7x10^5 PfSPZ small group and the 4.5x10^5 PfSPZ&#xD;
      larger group will be a minimum of three days.&#xD;
&#xD;
      After review of at least +14 days post vaccination, safety data for Groups 2b, 3b, 4a, 5a and&#xD;
      5b by the SMC, if there are no significant safety concerns, two volunteers (out of six) in&#xD;
      each of the Groups 4b and 5c will receive 9x10^5 PfSPZ, to demonstrate safety and&#xD;
      tolerability. At the same time, one (out of three) corresponding control volunteers will&#xD;
      receive NS, in order to maintain blinding. Approximately 24 hours later, provided criteria&#xD;
      for calling an ad hoc SMC meeting are not met, the remaining four volunteers in Group 4b and&#xD;
      5c will receive 9x10^5 PfSPZ dose of the vaccine, and the placebo recipients will receive NS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and type of Adverse Events</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards.&#xD;
Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination)&#xD;
Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination.&#xD;
Occurrence of serious adverse events during the study period.&#xD;
Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Antibodies against Pf proteins in volunteer sera</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1] by ELISA&#xD;
Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA.&#xD;
Analysis of antibodies to proteins in the Pf proteome array chip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitation of cellular immune responses against Pf proteins in volunteers</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Identification of number of vaccine induced PBMCs following Intracellular cytokine staining by flow cytometry after stimulation with PfSPZ or Pf-infected erythrocytes, peptide pools and P. falciparum infected primary human hepatocyte cell lines.&#xD;
Identification of numbers of vaccine induced CD4 and CD8 T cells following FluoroSpot assay after stimulation with PfSPZ or Pf-infected erythrocytes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole genome expression profiles of volunteer</measure>
    <time_frame>Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Human gene expression profiling focusing on immune response genes in volunteers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of adult volunteers protected against CHMI following immunization</measure>
    <time_frame>28 days post CHMI</time_frame>
    <description>Evidence of vaccine-mediated protection against CHMI 3 weeks after last immunization in Groups 1 (adults) by preventing blood stage infection for 28 days (as detected by blood smear analysis and qPCR) following CHMI.</description>
  </other_outcome>
  <other_outcome>
    <measure>Genetic profiles of Pf parasites</measure>
    <time_frame>Screening uptil 56 days post-CHMI or 56 days post-3rd immunization</time_frame>
    <description>Whole genome sequencing of Plasmodium falciparum following break through infections.</description>
  </other_outcome>
  <number_of_arms>23</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group 1a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1a (CHMI controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b (CHMI controls)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4a (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5c (PfSPZ Vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5c (normal saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Vaccine</intervention_name>
    <description>Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)</description>
    <arm_group_label>Group 1a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 1b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 2a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 2b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 3a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 3b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 4a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 4b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 5a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 5b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 5c (PfSPZ Vaccine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>0.9% Sodium chloride</description>
    <arm_group_label>Group 1a (normal saline)</arm_group_label>
    <arm_group_label>Group 1b (normal saline)</arm_group_label>
    <arm_group_label>Group 2a (normal saline)</arm_group_label>
    <arm_group_label>Group 2b (normal saline)</arm_group_label>
    <arm_group_label>Group 3a (normal saline)</arm_group_label>
    <arm_group_label>Group 3b (normal saline)</arm_group_label>
    <arm_group_label>Group 4a (normal saline)</arm_group_label>
    <arm_group_label>Group 4b (normal saline)</arm_group_label>
    <arm_group_label>Group 5b (normal saline)</arm_group_label>
    <arm_group_label>Group 5c (normal saline)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfSPZ Challenge (for CHMI)</intervention_name>
    <description>live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge</description>
    <arm_group_label>Group 1a (CHMI controls)</arm_group_label>
    <arm_group_label>Group 1a (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 1a (normal saline)</arm_group_label>
    <arm_group_label>Group 1b (CHMI controls)</arm_group_label>
    <arm_group_label>Group 1b (PfSPZ Vaccine)</arm_group_label>
    <arm_group_label>Group 1b (normal saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females, based on clinical and laboratory findings&#xD;
&#xD;
          -  From the age 6 months to 45 years&#xD;
&#xD;
          -  Adults with a Body Mass Index (BMI) 18 to 30 Kg/m2; or adolescents, children and&#xD;
             infants with Z-score of the selected indicator ([weight-for-height], [(height and BMI)&#xD;
             for age]) category within Â±2SD as detailed in protocol&#xD;
&#xD;
          -  Long term (at least one year) or permanent residence in the Bagamoyo town or nearby&#xD;
             villages&#xD;
&#xD;
          -  Agreement to release medical information and to inform the study doctor concerning&#xD;
             contraindications for participation in the study&#xD;
&#xD;
          -  Willingness to be attended to by a study clinician and take all necessary medications&#xD;
             prescribed during study period&#xD;
&#xD;
          -  Agreement to provide contact information of a third party household member or close&#xD;
             friend to study team&#xD;
&#xD;
          -  Availability through mobile phone 24 hours during the entire study period&#xD;
&#xD;
          -  Agreement not to participate in another clinical trial during the study period&#xD;
&#xD;
          -  Agreement not to donate blood during the study period&#xD;
&#xD;
          -  Able and willing to complete the study visit schedule over the study follow up period,&#xD;
             including the hospitalizations required for protocol compliance&#xD;
&#xD;
          -  Willingness to undergo HIV, hepatitis B (HBV) and hepatitis C (HCV) tests&#xD;
&#xD;
          -  Volunteer (subjects 18 years of age and older) and parent or guardian signing informed&#xD;
             consent (for subjects &lt;18 years of age) is able to demonstrate their understanding of&#xD;
             the study by responding correctly to 10 out of 10 true/false statements (in a maximum&#xD;
             of two attempts for those who failed to respond correctly to all true/false statements&#xD;
             in the first attempt)&#xD;
&#xD;
          -  Signed written informed consent, in accordance with local practice, provided by adult&#xD;
             volunteers, parents or legal representatives and relevant assent for children&#xD;
             participants as applicable&#xD;
&#xD;
          -  Free from malaria parasitaemia by blood smear at enrolment&#xD;
&#xD;
          -  Free from helminth infections at enrolment, or diagnosed with helminthes and treated&#xD;
             appropriately to eliminate infestation&#xD;
&#xD;
          -  Female volunteers aged 9 years and above must be non-pregnant (as demonstrated by a&#xD;
             negative serum pregnancy test), and provide consent / assent of their willingness to&#xD;
             take protocol-defined measures not to become pregnant during the study and safety&#xD;
             follow-up period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous receipt of an investigational malaria vaccine or drug in the last 5 years&#xD;
&#xD;
          -  Participation in any other clinical study involving investigational medicinal products&#xD;
             within 30 days prior to the onset of the study or during the study period&#xD;
&#xD;
          -  History of arrhythmias or prolonged QT-interval or other cardiac disease, or&#xD;
             Clinically significant abnormalities in electrocardiogram (ECG) at screening&#xD;
&#xD;
          -  Positive family history in a 1st or 2nd degree relative for cardiac disease at age &lt;50&#xD;
             years old&#xD;
&#xD;
          -  A history of psychiatric disease&#xD;
&#xD;
          -  Suffering from any chronic illness including; diabetes mellitus, cancer or HIV/AIDS&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immune-deficient condition, including&#xD;
             asplenia&#xD;
&#xD;
          -  History of drug or alcohol abuse interfering with normal social function&#xD;
&#xD;
          -  The use of chronic immunosuppressive drugs or other immune modifying drugs within&#xD;
             three months of study onset (inhaled and topical corticosteroids are allowed) and&#xD;
             during the study period&#xD;
&#xD;
          -  Any clinically significant deviation from the normal range in biochemistry or&#xD;
             hematology blood tests or in urine analysis&#xD;
&#xD;
          -  Positive HIV, hepatitis B virus or hepatitis C virus tests&#xD;
&#xD;
          -  Volunteers who are suspected as having clinically active TB by history or physical&#xD;
             examination with positive QuantiFERON-TB Gold Test In-Tube assay&#xD;
&#xD;
          -  Symptoms, physical signs and laboratory values suggestive of systemic disorders&#xD;
             including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency,&#xD;
             psychiatric, and other conditions which could interfere with the interpretation of the&#xD;
             study results or compromise the health of the volunteers&#xD;
&#xD;
          -  Any medical, social condition, or occupational reason that, in the judgment of the&#xD;
             investigator, is a contraindication to protocol participation or impairs the&#xD;
             volunteer's ability to give informed consent, increases the risk to the volunteer&#xD;
             because of participation in the study, affect the ability of the volunteer to&#xD;
             participate in the study or impair interpretation of the study data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Said Jongo, MD, MMED</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ifakara Health Institute (IHI), Bagamoyo, Tanzania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bagamoyo Research and Training center of the Ifakara Health Institute</name>
      <address>
        <city>Bagamoyo</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PfSPZ Vaccine</keyword>
  <keyword>Plasmodium falciparum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

